Surrozen prices $60 million stock offering at $31.67 per share
The Wnt pathway biotech will sell 1,894,540 shares, with closing expected November 16, 2026, and net proceeds earmarked for working capital and R&D.
SEC filing (2)
4 stories
The Wnt pathway biotech will sell 1,894,540 shares, with closing expected November 16, 2026, and net proceeds earmarked for working capital and R&D.
SEC filing (2)
Surrozen reported the first patient dosed in its SZN-8141 Phase 1b/2a trial and a planned Phase 2a enrollment increase, alongside added capital extending cash runway into 2029.
SEC filing
The financing, triggered by FDA clearance of the SZN-8141 IND, gives Surrozen cash runway into 2029 to run the DUET Phase 1b/2a study and start SZN-8143 development.
SEC filing
The clearance satisfies a funding condition from Surrozen's 2025 private placement, with a second closing expected around October 20, 2026.
SEC filing